Advertisement

FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman’s disease

  • Rob Barker
  • Fahrad Kazmi
  • Justin Stebbing
  • Sarah Ngan
  • Roger Chinn
  • Mark Nelson
  • Michael O’Doherty
  • Mark BowerEmail author
Short Communication

Abstract

Purpose

To evaluate the role of FDG-PET/CT scanning in the management of HIV-associated multicentric Castleman’s disease (MCD) a rare lymphoproliferative disorder associated with infection by human herpesvirus 8 (HHV8).

Materials and methods

Nine patients with histologically confirmed MCD underwent fused FDG-PET/CT scans at initial MCD diagnosis (n = 3), at MCD relapse (n = 4), or during remission (n = 2). All seven patients with active MCD had markedly elevated plasma HHV8 viral loads, but the patients in remission had no HHV8 viraemia. The three patients with newly diagnosed MCD were not on antiretroviral therapy at the time of imaging, but the other six were all on fully suppressive antiretroviral regimens.

Results

In the seven patients with active MCD (newly diagnosed or relapse) 33/91 lymph node groups (36%) included radiologically enlarged nodes on the CT scan, whilst 57/91 lymph node groups (63%) showed enhanced FDG uptake on the PET scan. In scans from patients in remission, there were no enlarged lymph nodes on the CT scan but 3 lymph nodes (11%) demonstrated enhanced FDG uptake. The median SUV recorded for the seven patients with active MCD was 4.8 (range 2.6–9.3) which was significantly higher than the median value of 2.5 recorded for the patients in remission (Mann-Whitney U test, p = 0.011).

Conclusion

Despite the small number of patients, in HIV-positive individuals with active MCD, FDG-PET scans more frequently detected abnormal uptake than CT scans detected enlarged lymph nodes. FDG-PET scanning has a useful role in the management of HIV-associated MCD in selecting appropriate sites for biopsy, and in staging and monitoring these lymphoproliferations.

Keywords

HIV MCD imaging PET/CT imaging Lymphoproliferations 

References

  1. 1.
    Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ. HIV-associated multicentric Castleman’s disease. Am J Hematol 2008;83:498–503.PubMedCrossRefGoogle Scholar
  2. 2.
    Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007;147:836–9.PubMedGoogle Scholar
  3. 3.
    Kojima M, Nakamura S, Shimizu K, Suda Y, Kasuga Y, Sugihara S, et al. Nodal marginal zone B-cell lymphoma resembling plasmacytoma arising from a plasma cell variant of localized Castleman’s disease: a case report. APMIS 2002;110:523–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Venizelos I, Tamiolakis D, Simopoulos C, Nikolaidou S, Barbagadaki S, Lambropoulou M, et al. Diffuse large B-cell lymphoma arising from a multicentric mixed variant of Castleman’s disease. Indian J Cancer 2004;41:135–7.PubMedGoogle Scholar
  5. 5.
    Chan JK, Tsang WY, Ng CS. Follicular dendritic cell tumor and vascular neoplasm complicating hyaline-vascular Castleman’s disease. Am J Surg Pathol 1994;18:517–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Zarate-Osorno A, Medeiros LJ, Danon AD, Neiman RS. Hodgkin’s disease with coexistent Castleman-like histologic features. A report of three cases. Arch Pathol Lab Med 1994;118:270–4.PubMedGoogle Scholar
  7. 7.
    Chim CS, Choi FP, Ooi GC, Kwong YL. Absence of gallium uptake in multicentric Castleman’s disease of plasma cell type. Haematologica 2001;86:442–3.PubMedGoogle Scholar
  8. 8.
    Murphy SP, Nathan MA, Karwal MW. FDG-PET appearance of pelvic Castleman’s disease. J Nucl Med 1997;38:1211–2.PubMedGoogle Scholar
  9. 9.
    Kunishima S, Taniguchi H, Koh T, Yamaguchi A, Yamagishi H. F-18 fluorodeoxyglucose positron emission tomography in mesenterial Castleman’s lymphoma. Clin Nucl Med 2001;26:789–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Blockmans D, Maes A, Stroobants S, Bobbaers H, Mortelmans L. FDG positron emission tomographic scintigraphy can reveal Castleman’s disease as a cause of inflammation. Clin Nucl Med 2001;26:975–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Reddy MP, Graham MM. FDG positron emission tomographic imaging of thoracic Castleman’s disease. Clin Nucl Med 2003;28:325–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Enomoto K, Nakamichi I, Hamada K, Inoue A, Higuchi I, Sekimoto M, et al. Unicentric and multicentric Castleman’s disease. Br J Radiol 2007;80:e24–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Hillier JC, Shaw P, Miller RF, Cartledge JD, Nelson M, Bower M, et al. Imaging features of multicentric Castleman’s disease in HIV infection. Clin Radiol 2004;59:596–601.PubMedCrossRefGoogle Scholar
  14. 14.
    Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52–9.PubMedCrossRefGoogle Scholar
  16. 16.
    O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997;38:1575–83.PubMedGoogle Scholar
  17. 17.
    Dieval C, Bonnet F, Mauclere S, Masquelier B, Bentaberry F, Cazeau A, et al. Multicentric Castleman disease: use of HHV8 viral load monitoring and positron emission tomography during follow-up. Leuk Lymphoma 2007;48:1881–3.PubMedCrossRefGoogle Scholar
  18. 18.
    Brust D, Polis M, Davey R, Hahn B, Bacharach S, Whatley M, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 2006;20:985–93.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Rob Barker
    • 1
  • Fahrad Kazmi
    • 1
  • Justin Stebbing
    • 1
  • Sarah Ngan
    • 2
  • Roger Chinn
    • 1
  • Mark Nelson
    • 3
  • Michael O’Doherty
    • 4
  • Mark Bower
    • 2
    Email author
  1. 1.Department of RadiologyImperial College School of Medicine, The Chelsea and Westminster HospitalLondonUK
  2. 2.Department of OncologyImperial College School of Medicine, The Chelsea and Westminster HospitalLondonUK
  3. 3.Department of HIV MedicineImperial College School of Medicine, The Chelsea and Westminster HospitalLondonUK
  4. 4.Clinical PET Centre, Guys and St. Thomas Hospital TrustSt. Thomas’ HospitalLondonUK

Personalised recommendations